ArticleJournal of arrhythmia2026
Divergent Atrial Transcriptomic Signatures in Diabetic and Nondiabetic Atrial Fibrillation.
Article in Journal of arrhythmia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetes mellitus (DM) increases the risk of atrial fibrillation (AF), but the molecular mechanisms underlying DM-related atrial remodeling remain unclear. This study aimed to characterize transcriptomic differences, including microRNA (miRNA) profiles, between atrial tissue from AF patients with and without DM. Methods: Right atrial appendage samples were collected from 12 patients with AF undergoing cardiac surgery (six with DM and six without DM). Total RNA was analyzed by high-throughput RNA sequencing. Differentially expressed genes (DEGs) and miRNAs were identified using Welch's Results: Forty-six protein-coding genes and nine miRNAs were differentially expressed between the two groups. Upregulated genes in the DM group, including Conclusions: Transcriptomic profiling revealed that AF with DM is characterized by enhanced mitochondrial metabolism, suppressed immune pathways, and altered miRNA expression. These findings suggest that DM modifies the atrial substrate through metabolic and epigenetic mechanisms, providing novel insights into AF pathogenesis in diabetic patients.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.